statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported...

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced...

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

MEI Pharma, Inc. (NASDAQ:MEIP  Get Free Report) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 9,100 shares, a...

Short Interest in MEI Pharma, Inc. (NASDAQ:MEIP) Decreases By 27.2%

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma files for $100M mixed shelf...

MEI Pharma files for $100M mixed shelf

StockNews.com downgraded shares of MEI Pharma (NASDAQ:MEIP  Free Report) from a buy rating to a hold rating in a report released on Tuesday morning. Separately, TheStreet downgraded MEI Pharma...

MEI Pharma (NASDAQ:MEIP) Stock Rating Lowered by StockNews.com

MEI Pharma (NASDAQ:MEIP  Get Free Report) had its target price reduced by investment analysts at Stifel Nicolaus from $8.00 to $7.00 in a research note issued to investors on Wednesday...

Stifel Nicolaus Lowers MEI Pharma (NASDAQ:MEIP) Price Target to $7.00

Glancy Prongay & Murray LLP (GPM) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors and officers possible violations of state laws. If you own...

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.

Volume	17,147.00
52-Wk High	$6.91
52-Wk Low	$3.01

MEIP MEI Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals